FDA Brief

Warning letters Devices

FDA warning letter to

Unomedical Device S.A. de C.V.

High riskIssued Jan 8Posted Feb 3Center for Devices and Radiological Health

FDA warns Unomedical over insulin infusion sets with unvalidated leak tests and unreported serious injuries.

What happened

FDA reviewed records from a Remote Regulatory Assessment of the Reynosa, Mexico facility from July 23 through August 8, 2025, under records requests dated May 22 and June 6, 2025. FDA found the water leak test for insulin infusion sets had not been validated despite more than 5,000 leak complaints from January 2023 to June 2025, including hyperglycemia and diabetic ketoacidosis. FDA also found over 41,000 Type 1 complaints were closed without investigation because lot numbers were missing, CAPA effectiveness checks were inadequate, and required Medical Device Reports were not submitted for serious injuries and a reportable malfunction.

What FDA found

  1. FDA says Unomedical did not validate the water leak test used for in-process and final inspection, complaint investigations, and validation, although the test is critical for detecting leaks in insulin infusion sets.

    21 CFR 820.75(a)
  2. FDA says Unomedical's complaint procedure allowed more than 41,000 Type 1 complaints, including leaks, infections and a death, to be closed without investigation because lot numbers were missing.

    21 CFR 820.198(c)
  3. FDA says Unomedical's corrective and preventive action (CAPA) system was inadequate, including effectiveness checks that excluded uninvestigated complaints and did not consider leak nonconformances or distributed product risk.

    21 CFR 820.100(a)
  4. FDA says Unomedical did not submit Medical Device Reports within 30 calendar days for four AutoSoft XC infusion set leak events in Complaint 1997347 that were reportable serious injuries.

    21 CFR 803.50(a)(1); 803.12(a); 803.52
  5. FDA says Unomedical did not submit Medical Device Reports within 30 calendar days for two AutoSoft XC leak events in Complaint 2051281 that were reportable malfunctions.

    21 CFR 803.50(a)(2); 803.12(a); 803.52
  6. FDA says Unomedical closed CAPA 1668046 as effective for Inset Guard Ramp-Up even though about 5,000 leak complaints continued through June 2025.

    21 CFR 820.100(a)

What FDA wants

FDA tells Unomedical to notify the office in writing within 15 business days of the specific steps taken, include documentation of corrections and corrective actions, and give a timetable for any longer-term work; it also asks for revised procedures and completed validation, CAPA and retrospective review results.

Who should pay attention

  • diabetes patients and clinicians using insulin pumps
  • brands that distribute Unomedical infusion sets under their own names
  • makers and buyers of infusion sets and components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  4. BMC Medical Co., Ltd.

    BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.

    High risk